You Can’t Steal an Idea. So Why Can You Own One?

For most of my life I never thought twice about patents, copyrights, trademarks. They seemed like furniture, just part of how the world is built, the kind of thing nobody questions because everybody grew up standing on it. Then a friend asked me a question that took the furniture apart in about ten seconds: if I steal your car, you no longer have a car. If I steal your idea, you still have your idea. So what, exactly, did I take?

That question is the whole argument, and it’s worth sitting with before deciding whether the conclusion is comfortable.

Theft, in every meaningful sense, requires exclusivity. If I take your car, there is now one car and two people who want it, you and me, and only one of us can have it. That scarcity is the entire reason theft is wrong, I’ve made you worse off to make myself better off. But an idea doesn’t work that way. If I copy your idea for a car, we both now have it. You’ve lost nothing you can point to. You can still build your version, still sell it, still improve it. What you’ve actually lost is exclusivity, the ability to stop me from also having it, which is a different thing than losing the idea itself. Economists have a term for goods that behave this way: non-rivalrous, meaning one person’s use of them doesn’t reduce anyone else’s. Physical property is rivalrous. Ideas are not.

Patents, copyrights, and trademarks are the legal machinery that makes a non-rivalrous good behave, by force of law, like a rivalrous one. That’s an abstract point until you apply it somewhere that costs people real money, and there’s no better place to apply it than medicine.

A patented drug is, at bottom, nature arranged in a particular molecular configuration to produce a healing effect in the human body. The company that patents it didn’t invent the underlying chemistry, they discovered how to combine and deliver it. Once they have, the patent grants them the exclusive legal right to be the only seller for years, sometimes decades once extensions and reformulations are accounted for, which means the price isn’t set by what it costs to make the pill. It’s set by what a monopoly can extract from people who, in the case of a life-saving drug, don’t have the option of declining to buy.

Now, the honest case for that arrangement, and it is an honest case, is the incentive argument. Developing a new drug costs more than a billion dollars, often several, and the better part of a decade, most of which is spent on trials that fail. If a competitor could copy the winning formula the moment it clears the FDA, without bearing any of that cost or risk, nobody would take the bet in the first place. Patents exist to let the company that took the risk recoup it. That’s not a strawman. That’s the real argument, and it deserves better than the assumption that anyone defending it is simply greedy.

None of this is theoretical, either. Entire industries innovate constantly without any legal monopoly and do just fine. Fashion design in the United States has almost no copyright protection, a dress can be copied by a competitor within weeks, yet the industry moves at a pace that would make a pharmaceutical company dizzy, driven by nothing more than the advantage of being first to market and the brand loyalty that comes with actually being the originator. Stand-up comedy has no copyright protection for jokes at all, comedians police theft through reputation and industry blacklisting, not lawsuits, and new material still gets written every single night. Recipes have never been patentable or copyrightable anywhere, and restaurants still keep inventing new dishes, because being first still earns you the credit, the customers, and the price premium before anyone else catches up. The incentive to create was never really “legal monopoly or nothing.” It was always some mix of being first, being trusted, and being better, with the legal monopoly layered on top of incentives that were already doing most of the work.

Here’s where it breaks down anyway. First, a large share of the foundational research behind new drugs, sometimes the majority of it, traces back to publicly funded work at universities and NIH labs, long before a private company licenses the result, finishes the trials, and patents the whole thing. The public frequently pays for the hardest, riskiest part of the science twice: once through tax dollars for the research, and again through drug prices for the patent. Second, watch what happens to price the moment a patent expires. Generic competition routinely collapses the price by eighty percent or more within the first year, on a chemically identical product. That gap, between the patented price and the generic price, is not the cost of the risk. It’s the cost of the exclusivity, priced separately, and it’s far larger than any reasonable accounting of R&D would require. Third, companies have gotten very good at extending that exclusivity well past the point the incentive argument justifies: minor reformulations, new delivery methods, evergreening tactics designed to reset the clock on drugs that have already paid for themselves many times over.

None of that proves patents should disappear entirely tomorrow. It proves something more specific and, I think, more defensible: the incentive argument justifies a patent system scoped tightly to actually recouping risk, not an indefinite monopoly on something as consequential as whether a family can afford to keep someone alive. I recently made the parallel case about taxation, in “You Are the Rich Person in This Argument,” that a genuine public-goods argument doesn’t automatically justify however large a claim gets built on top of it. Same principle, different lever. The honest version of an argument is never permission to stop checking whether the system built on it still matches the reason it was built.

You can’t steal an idea. You can only stop someone else from using it. Whether that’s worth doing, and for how long, is a question with a real answer. It’s just usually not the one currently written into law.